HRTX Heron Therapeutics Inc.

25.57
+0.01  (+0%)
Previous Close 25.56
Open 25.37
Price To Book 8.07
Market Cap 2,302,615,883
Shares 90,051,462
Volume 42,753
Short Ratio
Av. Daily Volume 1,100,946
Stock charts supplied by TradingView

NewsSee all news

  1. Health Canada Grants Priority Review Status for Heron Therapeutics' New Drug Submission for HTX-011 for Management of Postoperative Pain

    SAN DIEGO, Dec. 3, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some

  2. Heron Therapeutics to Present at the Evercore ISI HealthCONx Conference

    SAN DIEGO, Nov. 26, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some

  3. Heron Therapeutics to Present at the Stifel 2019 Healthcare Conference

    SAN DIEGO, Nov. 13, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some

  4. Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2019 and Highlights Recent Corporate Updates

    SAN DIEGO, Nov. 12, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some

  5. Heron Announces FDA Approval of Supplemental New Drug Application to Expand CINVANTI® Label for Single-Dose Regimen for Patients Receiving Moderately Emetogenic Chemotherapy (MEC)

    SAN DIEGO, Oct. 22, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

PDUFA date March 26, 2020.
HTX-011
Post operative pain
CRL Mar 28 2013. Approved August 10 2016.
APF530 - Sustol
Prevention of acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV)
FDA additional approval allowing IV injection in addition to current IV infusion.
CINVANTI (HTX-019)
Prevention of chemotherapy-induced nausea and vomiting (CINV)
Phase 3b data released October 3, 2019.
HTX-011
Total knee arthroplasty

Latest News

  1. Health Canada Grants Priority Review Status for Heron Therapeutics' New Drug Submission for HTX-011 for Management of Postoperative Pain

    SAN DIEGO, Dec. 3, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some

  2. Heron Therapeutics to Present at the Evercore ISI HealthCONx Conference

    SAN DIEGO, Nov. 26, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some

  3. Heron Therapeutics to Present at the Stifel 2019 Healthcare Conference

    SAN DIEGO, Nov. 13, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some

  4. Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2019 and Highlights Recent Corporate Updates

    SAN DIEGO, Nov. 12, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some

  5. Heron Announces FDA Approval of Supplemental New Drug Application to Expand CINVANTI® Label for Single-Dose Regimen for Patients Receiving Moderately Emetogenic Chemotherapy (MEC)

    SAN DIEGO, Oct. 22, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some

  6. Heron Therapeutics Announces Pricing of Public Offering of Common Stock

    SAN DIEGO, Oct. 3, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. ("Heron") (NASDAQ:HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments

  7. Heron Therapeutics Announces Proposed Public Offering of Common Stock

    SAN DIEGO, Oct. 3, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. ("Heron") (NASDAQ:HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments

  8. Heron Announces Positive Topline Results from Phase 3b Clinical Study of HTX-011 in Total Knee Arthroplasty

    SAN DIEGO, Oct. 2, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some

  9. Heron Therapeutics Appoints Kimberly Manhard to Board of Directors

    SAN DIEGO, Oct. 1, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some

  10. Heron Therapeutics Appoints Stephen Davis to Board of Directors

    SAN DIEGO, Oct. 1, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some

  11. Heron Therapeutics Resubmits New Drug Application to FDA for HTX-011 for the Management of Postoperative Pain

    SAN DIEGO, Oct. 1, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some

  12. Heron Therapeutics to Present at the 2019 Cantor Global Healthcare Conference

    SAN DIEGO, Sept. 25, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some